The Conversation (0)
CorMedix provided an update on its pre-clinical and clinical development programs to shareholders.
CorMedix (NYSEMKT:CRMD) provided an update on its pre-clinical and clinical development programs to shareholders.
As quoted in the press release:
Development of Medical Devices that Incorporate Taurolidine
CorMedix has focused its R&D efforts to three initial medical device areas where taurolidine incorporation may add value and potentially improve patient outcomes. These include:
- Development of anti-microbial suture materials to prevent surgical site infections (SSIs)
- Development of antimicrobial hydrogels to help prevent infections in burns and other wounds as well as treat infections in those sites. The hydrogels may also be effective as treatments for diabetic foot ulcers.
- Development of non-woven antimicrobial meshes to prevent infection and graft failure following hernia repair and reconstructive surgery
The 2018 U.S. market is projected to be $1.7 billion for sutures, and $1.0 billion each for hydrogels and non-woven meshes.
Development of Anti-Microbial Suture materials
CorMedix has been successful in integrating multiple concentrations of taurolidine (2%-10%) into monofilament suture materials, where the taurolidine is dispersed throughout the matrix of the fibers (one prepared with a homopolymer of epsilon-caprolactone and another fiber composed of rho-dioxanone). Taurolidine could also be loaded onto the surface of multifilament suture materials by integrating the drug into the coating layer.
Click here to read the full press release.
Source: www.accesswire.com
